Home
Antengene

Antengene Market Share Analysis for May 2026

antengene corporation limited (“antengene”, sehk: 6996.hk) is a leading commercial-stage r&d-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of treating patients beyond borders.

Industry: N/A

Domainantengene.com

Year Founded2016

Employees51 - 200

Annual Revenue$75M - $100M

Antengene

Antengene (including company regionals)

antengene.com

See more website traffic and engagement information

Antengene Revenue up to May 2026 is 75M - 100M

revenue generated by Antengene top domains

Antengene top domains revenue over 3 years

Revenue for Antengene top domains

antengene.com75M - 100M

See more with Sales Intelligence

Total visits to Antengene's top domains

Understand Antengene market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

antengene.com1.4K

See more with Sales Intelligence

Avg. visit duration in Antengene's top domains

Analyze Antengene engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

antengene.com00:01:03

See more with Sales Intelligence

Avg. pageviews on Antengene's top domains

See how Antengene keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

antengene.com2.11

See more with Sales Intelligence

Antengene top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Antengene

These are the website technologies, by industry, used by Antengene top domains

Mobile (3)

Meta Viewport

Advertising (1)

PubMatic

Audio Video Media (1)

VideoJS

Content Management System (1)

WordPress

More Technologies

1

See all

News & Signals from Antengene

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAntengene Corporation is developing preclinical bispecific TCE candidate on Jun 22nd '26.Antengene also announced that it has entered into an option agreement ("Option Agreement") to grant K2 Therapeutics the option to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate.

NewsAntengene Corporation will attend event 2026 BIO International Convention on Jun 22nd '26.Shanghai and Hong Kong, PRC, June 11, 2026 - Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it will attend the 2026 BIO International Convention, taking place from June 22nd to 25th at the San Diego Convention Center in San Diego, California, United States.

NewsAntengene Corporation is developing ATG-201 on Jun 9th '26.The clinical trial application approval of ATG-201 by China's NMPA marks a critical step forward for Antengene as the company expands its strategic focus from oncology and hematology to include autoimmune diseases.